Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Cyril Yip and Shuofeng Yuan.
Cyril Yip
Connection Strength
0.434
Shuofeng Yuan
  1. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo. Antiviral Res. 2017 Sep; 145:33-43.
    View in: PubMed
    Score: 0.181
  2. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020 May; 1(1):e14-e23.
    View in: PubMed
    Score: 0.055
  3. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 02 15; 395(10223):514-523.
    View in: PubMed
    Score: 0.054
  4. Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy. Int J Mol Sci. 2019 Jan 17; 20(2).
    View in: PubMed
    Score: 0.050
  5. The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy. Antiviral Res. 2018 12; 160:38-47.
    View in: PubMed
    Score: 0.049
  6. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res. 2017 05; 141:29-37.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.